Schedule 13G ownership disclosure
Apellis Pharmaceuticals Inc
Security class unavailable · CUSIP: 03753U106
Event date: 2019-04-30
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,309,052
- Percent of class
- 12.1000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-19-031736
- Form type
- SC 13G
- Filer
- Kezar Life Sciences, Inc.
- CIK
- CIK 1645666
- Filed
- May 24, 2019
- Reporting period
- Apr 30, 2019
- Description
- Schedule 13G beneficial ownership